| USP订购编号 |
美国药典，USP分析标准品，英文名称，规格 |
CAS编号查询 |
UN编号对照 |
| USP-1082592 |
Butyl Anthranilate (1 mL) (List Chemical) |
7756-96-9 |
|
| 2922493800 |
|
|
|
| USP-1381742 |
Meradimate (500 mg/ampule) (Menthyl Anthranilate) (List Chemical) |
134-09-8 |
|
| 2922493800 |
|
|
|
| USP-1607299 |
Safrole (4 x 50 mg) (List Chemical) (5-allylbenzo-1,3-dioxole) |
94-59-7 |
UN3082 |
| USP-1002811 |
Acetaldehyde (3 x 1.1 mL) |
75-07-0 |
UN1089 |
| USP-1005706 |
Glacial Acetic Acid (3 x 1.5 mL ampules) |
64-19-7 |
UN2789 |
| USP-1006801 |
Acetone (1.5 mL/ampule; 3 ampules) |
67-64-1 |
UN1090 |
| USP-1009479 |
2-Acetylpyridine (1 g) |
1122-62-9 |
|
| 2933399095 |
|
|
|
| USP-1009901 |
Acetyltributyl Citrate (3 x 200 mg) |
77-90-7 |
UN3082 |
| USP-1009923 |
Acetyltriethyl Citrate (100 mg) |
77-89-4 |
|
| 2918150000 |
|
|
|
| USP-1012688 |
Alcohol Determination – Alcohol (5 mL/ampule; 5 ampules) |
64-17-5 |
|
| 2208909002 |
|
|
|
| USP-1012768 |
Alcohol (1.2 mL/ampule; 5 ampules) |
64-17-5 |
UN1170 |
| USP-1012772 |
Dehydrated Alcohol (1.2 mL/ampule; 5 ampules) |
64-17-5 |
UN1170 |
| USP-1013206 |
Almond Oil (1 g) |
8007-69-0 |
|
| 1515908100 |
|
|
|
| USP-1020008 |
Aminobutanol (500 mg) (1-Butanol, 2-amino-, (+/-)-) |
96-20-8 |
UN2735 |
| USP-1021077 |
Ethyl 3-Aminocrotonate (2 x 200 mg) (Ethyl (Z)-3-aminobut-2-enoate) |
626-34-6 |
UN1760 |
| USP-1029013 |
Amitriptyline Related Compound A (25 mg) (dibenzosuberone) |
1210-35-1 |
|
| 2914399000 |
|
|
|
| USP-1084259 |
Butyraldehyde (3 x 1.2 mL) |
123-72-8 |
UN1129 |
| USP-1086312 |
Calcitriol Solution (5 mL) (需冷链运输) |
N/A |
UN1230 |
| USP-1087494 |
Camellia Seed Oil (500 mg) |
225233-97-6 |
|
| 1515908100 |
|
|
|
| USP-1089161 |
Cannabidiol Solution (1 mL (1mg/mL)) |
13956-29-1 |
UN1230 |
| USP-1089172 |
Cannabinoid Acids Mixture (1 mL) |
NA |
UN1992 |
| USP-1089183 |
Cannabinoids Mixture (1 mL) |
NA |
UN1230 |
| USP-1090150 |
Canola Oil (1 g) |
120962-03-0 |
|
| 1514990000 |
|
|
|
| USP-1091028 |
Capric Alcohol (5 x 30 mg) |
112-30-1 |
UN3082 |
| USP-1091505 |
Caprylocaproyl Polyoxylglycerides (200 mg) |
N/A |
UN1760 |
| USP-1096826 |
Castor Oil (3 x 100 mg) (Mixture containing about 92% of Triricinolein) |
8001-79-4 |
|
| 1515300000 |
|
|
|
| USP-1097400 |
Cefamandole Nafate (250 mg) |
42540-40-9 |
|
| 2941906000 |
|
|
|
| USP-1102000 |
Cephalothin Sodium (200 mg) |
58-71-9 |
|
| 2941906000 |
|
|
|
| USP-1105280 |
Chia Seed Oil (3 x 1 g) |
93384-40-8 |
|
| 1515908100 |
|
|
|
| USP-1115705 |
Chloromethyl Isopropyl Carbonate (100 mg) |
35180-01-9 |
UN3082 |
| USP-1131009 |
Cholecalciferol (30 mg/ampule; 5 ampules) (Vitamin D3) |
67-97-0 |
UN2811 |
| USP-1133897 |
Cinnamaldehyde (3 x 100 mg) |
14371-10-9 |
|
| 2912290090 |
|
|
|
| USP-1142195 |
Cobamamide (3 x 100 mg) (5,6-Dimethylbenzimidazolyl-Co-5′-deoxyadenosylcobamide) |
13870-90-1 |
|
| 2936260000 |
|
|
|
| USP-1145207 |
Cod Liver Oil (1 g) |
8001-69-2 |
|
| 1504100000 |
|
|
|
| USP-1145477 |
Coix Seed Oil Extract (2 x 1 g) |
537-40-6 |
|
| 1302190200 |
|
|
|
| USP-1148806 |
Corn Oil (5 x 200 mg) |
8001-30-7 |
|
| 1515290040 |
|
|
|
| USP-1150207 |
Cottonseed Oil (1 g) |
8001-29-4 |
|
| 1512290040 |
|
|
|
| USP-1151709 |
Cumene (1.2 mL/ampule; 3 ampules) |
98-82-8 |
UN1918 |
| USP-1154015 |
Cyclizine Related Compound A (50 mg) (1-methylpiperazine) |
109-01-3 |
UN2734 |
| USP-1154605 |
Cyclohexylmethanol (1 mL/ampule; 2 ampules) |
100-49-2 |
|
| 2906195000 |
|
|
|
| USP-1154650 |
Allyl Cyclohexane Valerate (3 x 0.5 mL) |
7493-68-7 |
|
| 2915600000 |
|
|
|
| USP-1154707 |
Cyclomethicone 4 (200 mg) |
556-67-2 |
UN1993 |
| USP-1154809 |
Cyclomethicone 5 (200 mg) |
541-02-6 |
|
| 2931909000 |
|
|
|
| USP-1283415 |
Fosinopril Related Compound A (25 mg) ((4S)-4-cyclohexyl-[(4-phenylbutyl)phosphinyl]acetyl-L-proline) |
95399-71-6 |
|
| 2933995300 |
|
|
|
| USP-1283426 |
Fosinopril Related Compound B (25 mg) ((4S)-4-Cyclohexyl-1-[(R)-[(S)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]acetyl-D-proline propionate (ester), hemibarium salt, sesquihydrate) |
N/A |
|
| 2933997500 |
|
|
|
| USP-1283437 |
Fosinopril Related Compound C (15 mg) ((4S)-4-cyclohexyl-1-[(RS)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]-acetyl-L-proline propionate (ester), sodium salt) |
N/A |
|
| 2933997500 |
|
|
|
| USP-1283448 |
Fosinopril Related Compound D (15 mg) ((4R)-4-cyclohexyl-1-[(R)-[(S)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]acetyl-L-proline propionate (ester), sodium salt) |
N/A |
|
| 2933997500 |
|
|
|
| USP-1283459 |
Fosinopril Related Compound E (15 mg) ((4S)-4-phenyl-1-[(R)-[(S)-1-hydroxy-2-methyl-propoxy](4-phenylbutyl)phospinyl]acetyl-L-proline propionate (ester), sodium salt) |
N/A |
|
| 2933997500 |
|
|
|
| USP-1283470 |
Fosinopril Related Compound G (15 mg) ((4-phenylbutyl)phosphinyl acetic acid, disodium salt) |
N/A |
|
| 2931909000 |
|
|
|
| USP-1283481 |
Fosinopril Related Compound H (25 mg) (4-phenylbutyl phosphonic acid) |
46348-61-2 |
|
| 2931909000 |
|
|
|
| USP-1284000 |
Flurandrenolide (100 mg) |
1524-88-5 |
|
| 2937220000 |
|
|
|
| USP-1285308 |
Flurazepam Related Compound C (50 mg) (5-chloro-2-(2-diethylaminoethylamino)-2′-fluorobenzophenone hydrochloride) |
N/A |
|
| 2922390000 |
|
|
|
| USP-1285603 |
Flurazepam Related Compound F (50 mg) (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) |
2886-65-9 |
|
| 2933998350 |
|
|
|
| USP-1285750 |
Flurbiprofen (200 mg) |
5104-49-4 |
UN2811 |
| USP-1285760 |
Flurbiprofen Related Compound A (100 mg) (2-(4-Biphenylyl)propionic Acid) |
6341-72-6 |
|
| 2916399000 |
|
|
|
| USP-1285807 |
Flurbiprofen Sodium (200 mg) |
56767-76-1 |
|
| 2916399000 |
|
|
|
| USP-1285818 |
Fluticasone Propionate Related Compound J (15 mg) (6alpha, 9alpha-difluoro-11beta,17alpha-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carboxylic acid) |
28416-82-2 |
UN3077 |
| USP-1285829 |
Fluticasone Propionate Related Compound D (15 mg) (S-methyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxyandrosta-1,4-diene-17beta-carbothioate) |
73205-13-7 |
|
| 2937220000 |
|
|
|
| USP-1285840 |
Fluticasone Propionate Related Compounds Mixture (25 mg) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1285851 |
Flutamide (200 mg) |
13311-84-7 |
|
| 2924296000 |
|
|
|
| USP-1285862 |
o-Flutamide (50 mg) |
N/A |
|
| 2924296000 |
|
|
|
| USP-1285873 |
Fluticasone Propionate (100 mg) |
80474-14-2 |
|
| 2937220000 |
|
|
|
| USP-1285884 |
Fluticasone Propionate Resolution Mixture (25 mg) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1285895 |
Fluticasone Propionate System Suitability Mixture (25 mg) (Fluticasone Propionate and Fluticasone Propionate Related Compounds B, C and D) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1285909 |
Fluvoxamine Maleate (200 mg) |
61718-82-9 |
UN3077 |
| USP-1285910 |
Fluticasone Propionate Nasal Spray Resolution Mixture (25 mg) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1589029 |
Pyroglutamic Acid (30 mg) ((S)-5-Oxopyrrolidine-2-carboxylic acid) |
98-79-3 |
|
| 2933790002 |
|
|
|
| USP-1589040 |
Pyrroloquinoline Quinone Disodium (100 mg) |
1519046-70-8 |
|
| 2933998350 |
|
|
|
| USP-1592409 |
Quercetin (200 mg) |
6151-25-3 |
UN2811 |
| USP-1592704 |
Quetiapine Fumarate (200 mg) |
111974-72-2 |
UN3077 |
| USP-1592715 |
Quetiapine System Suitability (25 mg) (Mixture contains Quetiapine Fumarate and about 1% each of Quetiapine Related Compound B, Quetiapine Related Compound G and Quetiapine Desethoxy) |
N/A |
UN3077 |
| USP-1592737 |
Quetiapine Related Compound B (15 mg) (11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine dihydrochloride) |
111974-74-4 |
|
| 2934990005 |
|
|
|
| USP-1592781 |
Quetiapine Related Compound G (15 mg) (Dibenzo[b,f][1,4]thiazepin-11(10H)-one) |
3159/7/7 |
|
| 2934990005 |
|
|
|
| USP-1592792 |
Quetiapine Related Compound H (15 mg) (4-(Dibenzo[b,f][1,4]thiazepin-11-yl)-1-[2-(2-hydroxyethoxy)ethyl]piperazine 1-oxide) |
1076199-40-0 |
|
| 2934990005 |
|
|
|
| USP-1593401 |
Quinapril Hydrochloride (400 mg) |
82586-55-8 |
|
| 2933492250 |
|
|
|
| USP-1593412 |
Quinapril Related Compound A (50 mg) (Ethyl [3S-[(2R*), 3a, 11ab]]-1,3,4,6,11,11a-hexahydro-3-methyl-1,4-dioxo-a-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetate) |
103733-49-9 |
|
| 2933998350 |
|
|
|
| USP-1593423 |
Quinapril Related Compound B (50 mg) (3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-,[3S-[2[R*(R*)],3R*]]) |
82768-85-2 |
|
| 2933492250 |
|
|
|
| USP-1594506 |
Quinic Acid (200 mg) (Cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (-)-) |
77-95-2 |
|
| 2918195000 |
|
|
|
| USP-1595000 |
Quinidine Gluconate (200 mg) |
7054-25-3 |
UN2811 |
| USP-1595509 |
Quinidine Sulfate (500 mg) |
6591-63-5 |
|
| 2939200050 |
|
|
|
| USP-1596807 |
Quinine Hydrochloride Dihydrate (1 g) |
6119-47-7 |
|
| 2939200010 |
|
|
|
| USP-1597005 |
Quinine Sulfate (500 mg) |
207671-44-1 |
|
| 2939200010 |
|
|
|
| USP-1597504 |
Quininone (50 mg) |
84-31-1 |
|
| 2939200050 |
|
|
|
| USP-1597617 |
Quinoline Yellow (50 mg) |
8004-92-0 |
|
| 3204120000 |
|
|
|
| USP-1598019 |
Rabeprazole Sodium (250 mg) (2-({[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazole sodium salt hydrate) |
891191-56-3 |
|
| 2933399095 |
|
|
|
| USP-1603108 |
Ribose (300 mg) |
50-69-1 |
|
| 2940006000 |
|
|
|
| USP-1603800 |
Rifabutin (50 mg) |
72559-06-9 |
|
| 2941906000 |
|
|
|
| USP-1604009 |
Rifampin (300 mg) |
13292-46-1 |
|
| 2941906000 |
|
|
|
| USP-1604199 |
Rifampin-N-Oxide (25 mg) |
125833-03-6 |
|
| 2934990005 |
|
|
|
| USP-1604202 |
Rifampin Quinone (25 mg) (1,4-dideoxy-1,4-dihydro-3-[[[4-methyl-1-piperazinyl]imino]methyl]-1,4-dioxo-rifamycin) |
13983-13-6 |
|
| 2933599550 |
|
|
|
| USP-1604337 |
Riluzole (200 mg) |
1744-22-5 |
UN2811 |
| USP-1604494 |
Riociguat System Suitability Mixture II (25 mg) (This is a mixture containing riociguat, riociguat related compound A and riociguat related compound C) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1604508 |
Rimantadine Hydrochloride (300 mg) |
1501-84-4 |
|
| 2921300000 |
|
|
|
| USP-1604519 |
Riociguat (250 mg) |
625115-55-1 |
|
| 2933595960 |
|
|
|
| USP-1604527 |
Riociguat System Suitability Mixture (25 mg) (This is a mixture containing (approximately 0.2% of related compound B and 0.5% of related compound C) riociguat, riociguat related compound B and riociguat related compound C) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1604530 |
Rivaroxaban (200 mg) |
366789-02-8 |
|
| 2934990005 |
|
|
|
| USP-1604541 |
Rivaroxaban R-enantiomer (20 mg) ((R)-5-Chloro-N-({2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)thiophene-2-carboxamide) |
865479-71-6 |
|
| 2934990005 |
|
|
|
| USP-1604552 |
Rivaroxaban Related Compound B (20 mg) ((S)-N-({2-Oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)acetamide) |
1429334-00-8 |
|
| 2934990005 |
|
|
|
| USP-1604563 |
Rivaroxaban Related Compound D (20 mg) (1,3-Bis({(S)-2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)urea) |
1365267-35-1 |
|
| 2934990005 |
|
|
|
| USP-1604574 |
Rivaroxaban Related Compound J (20 mg) |
1632463-24-1 |
|
| 2934990005 |
|
|
|
| USP-1604585 |
Rivaroxaban Related Compound H (20 mg) ((S)-4,5-Dichloro-N-({2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)thiophene-2-carboxamide) |
1770812-37-7 |
|
| 2934990005 |
|
|
|
| USP-1604596 |
Rivaroxaban Related Compound G (20 mg) ((S)-2-({2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)isoindoline-1,3-dione) |
446292-08-6 |
UN3077 |
| USP-1604600 |
Rimexolone (100 mg) |
49697-38-3 |
|
| 2937290000 |
|
|
|
| USP-1604610 |
Risedronate Sodium (350 mg) |
329003-65-8 |
|
| 2933399095 |
|
|
|
| USP-1604621 |
Risedronate Related Compound A (20 mg) ([1-Hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid), monohydrate) |
1220806-40-5 |
|
| 2933399095 |
|
|
|
| USP-1612867 |
Sibutramine Related Compound B (20 mg) (N-{1-[1-(3-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride) |
N/A |
|
| 2921490002 |
|
|
|
| USP-1612878 |
Sibutramine Related Compound C (20 mg) (N-{1-[1-(4-chlorophenyl)cyclobutyl]pentyl}-N,N-dimethylamine hydrochloride) |
N/A |
|
| 2921490002 |
|
|
|
| USP-1612889 |
Sibutramine Related Compound D (20 mg) (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine hydrochloride) |
84467-94-7 |
UN2811 |
| USP-1612903 |
Sitagliptin Phosphate (200 mg) |
654671-77-9 |
|
| 2933595960 |
|
|
|
| USP-1612914 |
Sitagliptin System Suitability Mixture (20 mg) (Sitagliptin Phosphate containing about 0.2% of S-enantiomer) |
N/A |
|
| 2933595960 |
|
|
|
| USP-1612947 |
Beta-Sitosterol (100 mg) |
83-46-5 |
|
| 2906130000 |
|
|
|
| USP-1613407 |
Sodium Acetate (1 g) |
127-09-3 |
|
| 2915292000 |
|
|
|
| USP-1613429 |
Sodium Acetate Trihydrate (1 g) |
6131-90-4 |
|
| 2915292000 |
|
|
|
| USP-1613462 |
Sodium Alginate (100 mg) |
9005-38-3 |
|
| 3913100000 |
|
|
|
| USP-1613509 |
Sodium Ascorbate (200 mg) |
134-03-2 |
|
| 2936270000 |
|
|
|
| USP-1613564 |
Sodium Benzoate (1 g) |
532-32-1 |
|
| 2916310002 |
|
|
|
| USP-1613597 |
Sodium Bromide (1 g) |
7647-15-6 |
UN3077 |
| USP-1613600 |
Sodium Butyrate (25 mg) |
156-54-7 |
|
| 2915600000 |
|
|
|
| USP-1613655 |
Sodium Bicarbonate (3 g) |
144-55-8 |
|
| 2836300000 |
|
|
|
| USP-1613688 |
Sodium Decanoyl Sarcosinate (30 mg) (Sodium N-decanoyl-N-methylglycinate) |
30377-07-2 |
|
| 2924190002 |
|
|
|
| USP-1613757 |
Sodium Carbonate Anhydrous (1 g) |
497-19-8 |
|
| 2836200000 |
|
|
|
| USP-1613804 |
Sodium Chloride (1 g) |
7647-14-5 |
|
| 2501000000 |
|
|
|
| USP-1613859 |
Sodium Citrate (1 g) |
6132/4/3 |
|
| 2918150000 |
|
|
|
| USP-1613860 |
Sodium Cyclamate (200 mg) |
139-05-9 |
|
| 2929909000 |
|
|
|
| USP-1613928 |
Sodium D-Pantoate (100 mg) |
60979-68-2 |
|
| 2918195000 |
|
|
|
| USP-1614159 |
Sodium Hyaluronate for IR Identification (250 mg) |
9067-32-7 |
|
| 3913908000 |
|
|
|
| USP-1614239 |
Sodium Iron EDTA (200 mg) |
18154-32-0 |
|
| 2922498050 |
|
|
|
| USP-1614308 |
Sodium Lactate (200 mg) |
867-56-1 |
|
| 2918110002 |
|
|
|
